ATE313325T1 - Indolcaroboxylsäure als thyroidrezeptor-liganden - Google Patents

Indolcaroboxylsäure als thyroidrezeptor-liganden

Info

Publication number
ATE313325T1
ATE313325T1 AT02256536T AT02256536T ATE313325T1 AT E313325 T1 ATE313325 T1 AT E313325T1 AT 02256536 T AT02256536 T AT 02256536T AT 02256536 T AT02256536 T AT 02256536T AT E313325 T1 ATE313325 T1 AT E313325T1
Authority
AT
Austria
Prior art keywords
indolcaroboxylic
acid
receptor ligand
thyroid receptor
thyroid
Prior art date
Application number
AT02256536T
Other languages
English (en)
Inventor
Gary Eric Pfizer Global Aspnes
Yuang-Ching Phoebe Chiang
Road
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE313325T1 publication Critical patent/ATE313325T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02256536T 2001-09-26 2002-09-20 Indolcaroboxylsäure als thyroidrezeptor-liganden ATE313325T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32538501P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ATE313325T1 true ATE313325T1 (de) 2006-01-15

Family

ID=23267668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02256536T ATE313325T1 (de) 2001-09-26 2002-09-20 Indolcaroboxylsäure als thyroidrezeptor-liganden

Country Status (9)

Country Link
US (1) US6723744B2 (de)
EP (1) EP1297833B1 (de)
JP (1) JP2003160559A (de)
AT (1) ATE313325T1 (de)
BR (1) BR0203877A (de)
CA (1) CA2404848C (de)
DE (1) DE60208132T2 (de)
ES (1) ES2253495T3 (de)
MX (1) MXPA02009472A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
GB0219022D0 (en) * 2002-08-15 2002-09-25 Karobio Ab Novel thyromimetic compounds
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
ES2346900T3 (es) * 2005-03-12 2010-10-21 Unilever N.V. Composiciones para el cuidado del cabello y/o el cuero cabelludo que incorporan compuestos amino-oxo-indol-ilideno.
JP4901853B2 (ja) * 2005-03-12 2012-03-21 ユニリーバー・ナームローゼ・ベンノートシヤープ テルペノイド化合物を含む頭髪および／または頭皮ケア組成物
ES2351159T3 (es) * 2005-03-12 2011-02-01 Unilever Plc Compuestos de amino-oxo-indol-ilideno para uso en el tratamiento de prurito en la piel del cuero cabelludo.
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
MX2007014502A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
AU2007265940A1 (en) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 6-5 System Bicyclic Heterocyclic Derivative And Its Pharmaceutical Utility
US20080206156A1 (en) * 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US8021649B2 (en) 2007-02-22 2011-09-20 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
EP2695611B1 (de) 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirom zur Verwendung bei der Vorbeugung und/oder Behandlung von Haarerkrankungen und Zusammensetzungen davon
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
CN106883153B (zh) * 2017-04-11 2018-11-13 河南工业大学 一种2-磺酰基-1,4-二酚衍生物的制备方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DE69314718T2 (de) 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
DE19808267A1 (de) 1998-02-27 1999-09-02 Messer France Sa Befüll- und Entnahmemodul für ein Kühlmodul und Verfahren zum Befüllen eines Kühlmoduls
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
HK1044532A1 (zh) 1999-03-01 2002-10-25 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
JP2003500459A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター 置換バイアリールエーテル化合物
AU3507800A (en) 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using diphenylmethane derivatives
EP1185229A1 (de) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Verfahren zur behandlung von haarausfall
JP2003500432A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
WO2000072810A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
WO2001070687A1 (de) * 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können
EP1148054B1 (de) * 2000-04-21 2005-11-23 Pfizer Products Inc. Thyroid-Rezeptorliganden
EP1347959A1 (de) * 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate

Also Published As

Publication number Publication date
MXPA02009472A (es) 2003-03-31
DE60208132D1 (de) 2006-01-26
EP1297833A1 (de) 2003-04-02
CA2404848C (en) 2006-07-04
US20030078289A1 (en) 2003-04-24
US6723744B2 (en) 2004-04-20
EP1297833B1 (de) 2005-12-21
DE60208132T2 (de) 2006-07-20
ES2253495T3 (es) 2006-06-01
BR0203877A (pt) 2003-09-16
CA2404848A1 (en) 2003-03-26
JP2003160559A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
DE60208132D1 (de) Indolcaroboxylsäure als Thyroidrezeptor-Liganden
ATE310733T1 (de) Thyroid-rezeptorliganden
ATE297905T1 (de) 6-azauracilderivate als liganden der thyroidrezeptoren
CA2363145A1 (en) Oxamic acids and derivatives as thyroid receptor ligands
PT1033364E (pt) Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
WO1998047505A9 (en) Neuropeptide y receptor antagonist
CA2332066A1 (en) Tetrazole compounds as thyroid receptor ligands
NO20016001D0 (no) Substituert fenylpropansyrederivater som agonister for human peroksisom proliferantaktivert reseptor (PPAR)<alfa>
EP1818325A3 (de) 3,4-DI-substituierte Cyclobuten-1,2-Dione als CXC-Chemokin-Rezeptorliganden
TR200003333T2 (tr) Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
CN1545409A (zh) 二苯乙烯类化合物在制备用于治疗和预防糖尿病或与逆转录病毒有关疾病的药物中用途
DE69524598D1 (de) Kondensierte imidazolderivate, ihre herstellung und verwendung
AU5343698A (en) New benzofuranone derivatives and a method for producing them
DE60020573D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
EP1253139A3 (de) Multioligoanilinierte Fullerene
DE60228429D1 (de) Medizinische zusammensetzung, die ein 1,3-thiazinderivat enthält
PT785787E (pt) Utilizacao de derivados de 1,5-benzodiazepina para o controlo de esvaziamento gastrico em doentes com diabetes mellitus nao-insulino dependentes
ATE401306T1 (de) Pyrrolderivat
BR0308987A (pt) Agentes antidiabéticos
EP1207158A4 (de) Substituierte benzylthiazolidin-2,4-dion derivate
AU2003260745A1 (en) Sulphonylamino derivatives for the treatment of alzheimer's disease
EP1897876A3 (de) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties